Glucon

Glucon is a development stage company with a focus on creating glucose monitoring devices for the diabetes market. The company's slogan "Experience seamless, precise, and real-time glucose monitoring with top-notch Photoacoustic technology in a compact, wearable device" encapsulates its mission. Utilizing a novel Photoacoustic technology, which is protected by several granted and pending patents, the devices are designed to be small and conveniently wearable, offering continuous, accurate, and real-time glucose monitoring for both clinical and personal use. Glucon has demonstrated the superior performance of Photoacoustics compared to optics alone, providing direct blood glucose measurements from inside blood vessels, enhancing both the specificity and sensitivity of glucose measurement. The company's desktop prototype device is currently undergoing extensive clinical trials. In terms of funding, Glucon received its last investment in the form of a Series D investment on 22 January 2007. The investors involved in this round included 3i Group, Giza Venture Capital, Quest Capital, Sequel Venture Partners, Covera Ventures, Ascend Technology Ventures, and MKI. With its innovative approach to glucose monitoring and ongoing clinical trials, Glucon presents an intriguing investment opportunity in the healthcare technology space.